Sprint Bioscience AB (publ)
Sprint Bioscience AB (publ) operates in various business sectors.
Sprint Bioscience AB (publ) (5JA1) - Net Assets
Latest net assets as of June 2024: €18.69 Million EUR
Based on the latest financial reports, Sprint Bioscience AB (publ) (5JA1) has net assets worth €18.69 Million EUR as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€48.30 Million) and total liabilities (€29.61 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €18.69 Million |
| % of Total Assets | 38.7% |
| Annual Growth Rate | -5.7% |
| 5-Year Change | 152.1% |
| 10-Year Change | N/A |
| Growth Volatility | 284.25 |
Sprint Bioscience AB (publ) - Net Assets Trend (2018–2023)
This chart illustrates how Sprint Bioscience AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sprint Bioscience AB (publ) (2018–2023)
The table below shows the annual net assets of Sprint Bioscience AB (publ) from 2018 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €27.77 Million | -1.47% |
| 2022-12-31 | €28.19 Million | -59.99% |
| 2021-12-31 | €70.45 Million | +670.49% |
| 2020-12-31 | €9.14 Million | -17.00% |
| 2019-12-31 | €11.02 Million | -70.42% |
| 2018-12-31 | €37.24 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sprint Bioscience AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16201600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €280.88 Million | 1011.29% |
| Total Equity | €27.77 Million | 100.00% |
Sprint Bioscience AB (publ) Competitors by Market Cap
The table below lists competitors of Sprint Bioscience AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Grom Social Enterprises Inc
NASDAQ:GROM
|
$1.77K |
|
TERNIENERGIA
MU:TI5
|
$1.77K |
|
Leopard Energy, Inc.
PINK:LEEN
|
$1.77K |
|
MEWAH INTL
BE:MWX
|
$1.78K |
|
Mind Gym Ltd
LSE:MIND
|
$1.77K |
|
Tavistock Investments Plc
LSE:TAVI
|
$1.77K |
|
Scoobeez Global Inc
PINK:SCBZ
|
$1.77K |
|
Koza Polyester Sanayi ve Ticaret A.S.
IS:KOPOL
|
$1.77K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sprint Bioscience AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 28,188,000 to 27,774,000, a change of -414,000 (-1.5%).
- Net loss of 438,000 reduced equity.
- New share issuances of 2,000 increased equity.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-438.00K | -1.58% |
| Share Issuances | €2.00K | +0.01% |
| Other Changes | €22.00K | +0.08% |
| Total Change | €- | -1.47% |
Book Value vs Market Value Analysis
This analysis compares Sprint Bioscience AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.47x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.07x to 0.47x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | €2.75 | €0.19 | x |
| 2019-12-31 | €0.67 | €0.19 | x |
| 2020-12-31 | €0.35 | €0.19 | x |
| 2021-12-31 | €1.50 | €0.19 | x |
| 2022-12-31 | €0.40 | €0.19 | x |
| 2023-12-31 | €0.40 | €0.19 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sprint Bioscience AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.58%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.87%
- • Asset Turnover: 0.81x
- • Equity Multiplier: 2.25x
- Recent ROE (-1.58%) is above the historical average (-162.43%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -59.65% | -123.86% | 0.30x | 1.59x | €-25.94 Million |
| 2019 | -195.48% | -64.21% | 1.74x | 1.75x | €-22.64 Million |
| 2020 | -467.98% | -253.43% | 0.51x | 3.65x | €-43.71 Million |
| 2021 | -35.60% | -71.43% | 0.44x | 1.12x | €-32.13 Million |
| 2022 | -214.30% | -7560.33% | 0.02x | 1.33x | €-63.23 Million |
| 2023 | -1.58% | -0.87% | 0.81x | 2.25x | €-3.22 Million |
Industry Comparison
This section compares Sprint Bioscience AB (publ)'s net assets metrics with peer companies in the same industry.
No peer company data available for comparison.